{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:11:07Z","timestamp":1773148267962,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014620","name":"Micropalaeontological Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014620","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.eururo.2025.09.008","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T19:23:12Z","timestamp":1758136992000},"page":"564-565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Challenging the Guidelines: Rethinking Neoadjuvant Therapy for Histologic Subtypes of Bladder Cancer"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2181-8405","authenticated-orcid":false,"given":"Miguel","family":"Zugman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari\u00ea","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando C.","family":"Maluf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.09.008_b0005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male genital organs\u2014part B: prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.008_b0010","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438640","article-title":"Current advances in the management of nonurothelial subtypes of bladder cancer","volume":"44","author":"Vlachou","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.eururo.2025.09.008_b0015","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.path.2022.07.003","article-title":"Urothelial carcinoma","volume":"15","author":"Gandhi","year":"2022","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.eururo.2025.09.008_b0020","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.09.008_b0025","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.09.008_b0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; Amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.09.008_b0035","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2019.09.035","article-title":"EAU-ESMO consensus statements on the management of advanced and variant bladder cancer\u2014an international collaborative multistakeholder effort","volume":"77","author":"Witjes","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.008_b0040","doi-asserted-by":"crossref","unstructured":"Raychaudhuri R, Khaki AR, Redman MW, et al. Neoadjuvant pembrolizumab and accelerated methotrexate, vinblastine, doxorubicin, and cisplatin in nonurothelial histologic subtypes of muscle-invasive bladder cancer: a phase 2 trial. Eur Urol 2025;88:559\u201363.","DOI":"10.1016\/j.eururo.2025.07.002"},{"key":"10.1016\/j.eururo.2025.09.008_b0045","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2025.09.008_b0050","doi-asserted-by":"crossref","first-page":"S1201","DOI":"10.1016\/j.annonc.2023.09.1012","article-title":"2363MO A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2)","volume":"34","author":"Szabados","year":"2023","journal-title":"Ann Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382500510X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382500510X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T21:50:33Z","timestamp":1773093033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382500510X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S030228382500510X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.09.008","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenging the Guidelines: Rethinking Neoadjuvant Therapy for Histologic Subtypes of Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}